Evaluation of WO2012080456 and WO2012080457; boheringer Ingleheim's first CXCR2 antagonists

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 3, 2013, Pages 383-388

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

Chemokine; COPD; CXCR2; IL 8; Inflammation

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 2 AMINOPHENOL; ARYLCARBONYL; ARYLSULFONYL; CARBONYL DERIVATIVE; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; DANIRIXIN; ELUBRIXIN; NAVARIXIN; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; IC 50; PROTEIN MODIFICATION;

AMINOPHENOLS; CHEMOTAXIS; HUMANS; INFLAMMATION; INTERLEUKIN-8; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, INTERLEUKIN-8B; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84874063627     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.754424     Document Type: Article

References (22)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1(6077):1645-8
2. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis 2012;7:95-9
3. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007;119(5):1055-62
4. Stockley RA. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin 2009;25(5):1235-45
5. Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 2002;1(1):19-25
6. Pease JE, Horuk R. Chemokine receptor antagonists: Part 2. Expert Opin Ther Pat 2009;19(2):199-221
7. Busch-Petersen J, Wang Y. Phenol-containing antagonists of the CXCR2 receptor. Expert Opin Ther Pat 2008;18(6):629-37
8. White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273(17):10095-8
9. SmithKline Beecham Corp. IL-8 Receptor Antagonists. WO1996025157; 1996
10. Dwyer MP, Yu Y, Chao J, et al. Discovery of 2-hydroxy-N,N-dimethyl-3-{2- [[(R)-1-(5- methylfuran-2-yl)propyl] amino]-3,4-dioxocyclobut-1-enylamino} benzamide (SCH 527123): A potent, orally bioavailable CXCR2/ CXCR1 receptor antagonist. J Med Chem 2006;49(26):7603-6
11. Boehringer Ingelheim International GmbH. Bicyclic ring system substituted amide functionalised phenols as medicaments. WO2012080456 ; 2012
12. Boehringer Ingelheim International GmbH. Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments. WO2012080457 ; 2012
13. Pharmacopeia, Inc. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands. US20040097547 ; 2004
14. Novartis AG. 3,4-Di-substituted cyclobutene-1,2-diones as CXCR2 receptor antagonists. WO2010063802 ; 2010
15. Novartis AG. Oragnic compounds. WO2010015613 ; 2010
16. Gonsiorek W, Fan X, Hesk D, et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/ CXCR2 antagonist. J Pharm Exp Ther 2007;322:477-85
17. Chapman RW, Minnicozzi M, Celly CS, et al. A novel, orally active CXCR1/ 2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007;322(2):486-93
18. Holz O, Khalilieh S, Ludwig-Sengpiel A, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010;35(3):564-70
19. Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: A randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012 ;42(7):1097-103 for navirixin
20. Ligand Pharmaceuticals, Inc. Presentation For Investor And Analyst Day - June 24, 2010
21. Available from: http://clinicaltrials.gov Long-Term Extension Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD (P05575AM2)(MK-7123-009-0) NCT01006616 (1 December 2011
22. Wolff M, Kredel S, Haasen D, et al. High content screening of CXCR2-dependent signalling pathways. Comb Chem High Throughput Screen 2010;13(1):3-15